Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4448 | ctDNA blood sampling Wiki | 1.00 |
| drug832 | Camostat Mesilate Wiki | 0.35 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D046152 | Gastrointestinal Stromal Tumors NIH | 1.00 |
| D001661 | Biliary Tract Neoplasms NIH | 1.00 |
| D001749 | Urinary Bladder Neoplasms NIH | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100574 | Biliary tract neoplasm HPO | 1.00 |
| HP:0009725 | Bladder neoplasm HPO | 1.00 |
| HP:0100723 | Gastrointestinal stroma tumor HPO | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100834 | Neoplasm of the large intestine HPO | 0.45 |
| HP:0100526 | Neoplasm of the lung HPO | 0.29 |
| HP:0002664 | Neoplasm HPO | 0.17 |
Navigate: Correlations HPO
There is one clinical trial.
This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease. Patients will attend 4 study visits over a period of up to 28 days.
Description: This outcome is defined as the time in days from randomization to the first of two consecutive negative RT-PCR results of self-collected nasal swabs.
Measure: Time until cessation of shedding of SARS-CoV-2 virus Time: Up to 28 daysDescription: Number of symptomatic patients with clinical worsening, defined as the development of respiratory distress or symptoms that require hospitalization.
Measure: Clinical worsening of COVID-19 disease in symptomatic patients Time: Up to 28 daysDescription: Number of patients that develop antibodies to SARS-CoV-2.
Measure: Development of antibodies to SARS-CoV-2 Time: Up to 28 daysDescription: This outcome is defined as absence of moderate or severe symptoms for at least 24 hours for those reporting moderate or severe symptoms at baseline
Measure: Time until resolution of symptoms Time: Up to 28 daysDescription: Progression of respiratory symptoms defined as a two-level increase of a symptom on the Daily Symptom Status Questionnaire within a 24 hour period, or a one-level increase of a symptom on the Daily Symptom Status Questionnaire observed/sustained for a consecutive 48 hour period.
Measure: Time until progression of symptoms Time: Up to 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports